Ishido K, Kimura N, Nagase H, Wakasa Y, et al. Limited Survival Benefit of Short-Course Neoadjuvant Gemcitabine Plus Nab-Paclitaxel for Resectable Pancreatic Cancer: A Prospective Phase II Study With a Propensity Score-Matched Analysis. J Surg Res 2026;328:74-84.
PMID: 42874369